Vera Jaime H, Garvey Lucy J, Allsop Joanna M, Kaye Steve, McClure Myra O, Back David, Taylor-Robinson Simon D, Winston Alan
Department of Medicine, Imperial College, and Clinical Trials Centre, St Mary's Hospital, Norfolk Place, London, UK.
HIV Clin Trials. 2012 Jul-Aug;13(4):222-7. doi: 10.1310/hct1304-222.
Cerebrospinal (CSF) fluid biomarkers may be a useful tool for assessing the cerebral effects of antiretroviral therapy.
The aim of the study was to investigate the relationship between 4 CSF chemokines with maraviroc exposure and cerebral metabolite ratios (CMR) measured by magnetic resonance spectroscopy (1H-MRS) in HIV-infected individuals following maraviroc intensification.
CSF concentration of maraviroc and 4 chemokines (MCP-1, IP-10, MCP-4, and MIP-1β), plasma concentration of maraviroc pre-CSF assessment, and right basal ganglia CMR were assessed in 12 male HIV-infected, neuro-asymptomatic adults after 14 days of antiretroviral therapy intensification with maraviroc 150 mg twice daily. The relationship between CSF analytes with both CMRs and plasma and CSF maraviroc concentrations were examined using Spearman correlation coefficient.
Twelve subjects completed study procedures with baseline values as follows: mean (SD) age 42 (8) years, CD4+ cell count 503 (199) cells/µL, and plasma HIV RNA<50 copies/mL in most subjects. Mean (range, pg/mL) chemokine concentrations were IP-10, 1242 (190-8073); MCP-4, 6.52 (1-18); MCP-1, 702 (201-1618); and MIP-1β, 42 (5-153). IP-10, MCP-4, and MIP-1β were significantly associated with CMRs in the right basal ganglia with (1) lower concentrations of IP-10 correlating with higher N-acetyl aspartate to creatine ratios (NAA/Cr) and (2) higher concentrations of MCP-4 and MIP-1β correlating with higher myoinositol to creatine (mI/Cr) ratios. There were no significant associations with MCP-1. Finally lower concentrations of IP-10 were significantly associated with higher maraviroc plasma trough concentration (r=-0.629, P=.028) but not CSF concentration (r=-0.308, P=.331).
We hypothesize that the relationship between IP-10, MCP-4, and MIP-1β with maraviroc exposure and CMRs may be associated with a direct cerebral effect of maraviroc.
脑脊液生物标志物可能是评估抗逆转录病毒疗法对大脑影响的有用工具。
本研究旨在调查在接受马拉维若强化治疗的HIV感染者中,4种脑脊液趋化因子与马拉维若暴露以及通过磁共振波谱(1H-MRS)测量的脑代谢物比率(CMR)之间的关系。
在12名感染HIV、无神经症状的成年男性中,在每天两次服用150mg马拉维若强化抗逆转录病毒治疗14天后,评估脑脊液中马拉维若和4种趋化因子(MCP-1、IP-10、MCP-4和MIP-1β)的浓度、脑脊液评估前血浆中马拉维若的浓度以及右侧基底节的CMR。使用Spearman相关系数检查脑脊液分析物与CMR、血浆和脑脊液中马拉维若浓度之间的关系。
12名受试者完成了研究程序,基线值如下:平均(标准差)年龄42(8)岁,CD4 +细胞计数503(199)个/µL,大多数受试者血浆HIV RNA<50拷贝/mL。趋化因子平均(范围,pg/mL)浓度为:IP-10,1242(190 - 8073);MCP-4,6.52(1 - 18);MCP-1,702(201 - 1618);MIP-1β,42(5 - 153)。IP-10、MCP-4和MIP-1β与右侧基底节的CMR显著相关,(1)IP-10浓度较低与较高的N-乙酰天门冬氨酸与肌酸比率(NAA/Cr)相关,(2)MCP-4和MIP-1β浓度较高与较高的肌醇与肌酸(mI/Cr)比率相关。与MCP-1无显著关联。最后,较低的IP-10浓度与较高的马拉维若血浆谷浓度显著相关(r = -0.629,P = 0.028),但与脑脊液浓度无关(r = -0.308,P = 0.331)。
我们假设IP-10、MCP-4和MIP-1β与马拉维若暴露和CMR之间的关系可能与马拉维若对大脑的直接作用有关。